Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Rain Oncology Inc. (RAIN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"RAIN ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 16,677 $ 13,555 General and administrative 5,066 3,895 Total operating expenses 21,743 17,450 Loss from operations Other income: Interest income 1,259 56 Total other income 1,259 56 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 36,339,851 26,511,743 SUMMARY CONDENSED CONSOLIDATED BALANCE SHEET DATA" |
|
| 03/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 19,078 $ 14,672 $ 61,400 $ 40,773 General and administrative 4,479 3,405 15,736 10,739 Total operating expenses 23,557 18,077 77,136 51,512 Loss from operations Other income: Interest and other income 882 94 1,415 120 Total other income 882 94 1,415 120 Net loss before income tax expense Income tax expense Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used to compute net loss per share, basic and diluted 32,288,083 26,470,600 27,985,446 19,405,833 SUMMARY CONSOLIDATED BALANCE SHEET DATA" |
|
| 03/03/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/10/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
8-K
| Quarterly results |
|
|